Prostate cancer is one of the most commonly diagnosed cancers in males, with 1.5M diagnoses globally in 2022. There is an unmet clinical need for the development of new biomarkers to inform clinical decision-making and avoid disease progression. Successful clinical trials have generated large volumes of clinico-genomic data, providing a unique opportunity to explore potential new targets and biomarkers across thousands of patients. However, these data are currently unable to be analysed in an integrated fashion, due to being stored in different formats and repositories across the globe. This variability makes bio-curation and effective data management essential to advancing prostate cancer research.
The Movember-SAiGENCI transformational integrated repository (MSTIR) aims to address this by building a scalable repository to receive, manage and analyse clinical trial data, incorporating initially the CHAARTED and ENZAMET trials. Ongoing work includes ethics approval, data use agreements with data providers, collecting, cleaning and harmonising multiple types of data, (including exome, transcriptome, H&E imaging, SNP array, plasma profiling and clinical covariates), while also building a secure back-end with a user-friendly front-end interface. The final repository will allow users to discover clinico-genomic trends and potential biomarkers across large cohorts of patients, increasing precision of care and improving patient outcomes.